

Abstract:

**Moebius Medical is an innovative clinical stage biotechnology company that is developing novel pain relief treatments for osteoarthritis. Osteoarthritis is a degenerative condition characterized by continuous breakdown and loss of cartilage and joint function. OA affects over 100 million people worldwide, and is very much associated with the aging population, as the prevalence of symptomatic knee osteoarthritis is greater than 12% in individuals over 60 years old. There is currently no cure for osteoarthritis, thus treatment goals are to reduce pain and restore joint functionality. Current symptomatic treatments, including hyaluronic acid, offer limited efficacy and have come under increased scrutiny.**

**Moebius's product is an intra-articular liposomal injection which is being developed to provide symptomatic relief of mild-to-moderate osteoarthritis pain. The technology is a 3-way license from academia in Israel, as it is based on the multidisciplinary cooperation between leading professors of three of Israel's prestigious research institutions: Prof. Yechezkel Barenholz of the Hebrew University, Prof. Izhak Etsion of the Technion Institute, and Prof. Dorit Nitzan of Hadassah Medical Center.**

**After taking the product through a first-in-man study, Moebius recently signed an agreement with Sun Pharmaceuticals, and global pharma giant based in India, who will fund the continued development and commercialization.**

**Moshe Weinstein, CEO**

Moebius Medical Ltd.

t. +972-58-433-8674